These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 32871586)

  • 21. Maximum standard uptake value of 18F-fluorodeoxyglucose positron emission tomography is a prognostic factor for progression-free survival of newly diagnosed patients with diffuse large B cell lymphoma.
    Miyazaki Y; Nawa Y; Miyagawa M; Kohashi S; Nakase K; Yasukawa M; Hara M
    Ann Hematol; 2013 Jan; 92(2):239-44. PubMed ID: 23079891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies.
    Vassilakopoulos TP; Papageorgiou SG; Angelopoulou MK; Chatziioannou S; Prassopoulos V; Karakatsanis S; Arapaki M; Mellios Z; Sachanas S; Kalpadakis C; Katodritou E; Leonidopoulou T; Kotsianidis I; Hatzimichael E; Kotsopoulou M; Dimou M; Variamis E; Boutsis D; Terpos E; Michali E; Karianakis G; Tsirkinidis P; Vadikolia C; Poziopoulos C; Pigaditou A; Vrakidou E; Siakantaris MP; Kyrtsonis MC; Symeonidis A; Anargyrou K; Papaioannou M; Chatziharissi E; Vervessou E; Tsirogianni M; Palassopoulou M; Gainaru G; Mainta C; Tsirigotis P; Assimakopoulou T; Konstantinidou P; Papadaki H; Dimopoulos MA; Pappa V; Karmiris T; Roussou P; Datseris I; Panayiotidis P; Konstantopoulos K; Pangalis GA; Rondogianni P
    Ann Hematol; 2021 Sep; 100(9):2279-2292. PubMed ID: 33523289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era.
    Kumar A; Lunning MA; Zhang Z; Migliacci JC; Moskowitz CH; Zelenetz AD
    Br J Haematol; 2015 Dec; 171(5):776-83. PubMed ID: 26456939
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The rate of reduction in the maximum standardized uptake value from the initial to the post-R-CHOP therapy in positron emission tomography scan predicts disease progression in diffuse large B cell lymphoma patients.
    Ishii Y; Tomita N; Tateishi U; Ishiyama Y; Yamamoto E; Hattori Y; Hagihara M; Yamazaki E; Ishigatsubo Y
    Med Oncol; 2014 Mar; 31(3):880. PubMed ID: 24504845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interobserver Agreement of Interim and End-of-Treatment
    Burggraaff CN; Cornelisse AC; Hoekstra OS; Lugtenburg PJ; De Keizer B; Arens AIJ; Celik F; Huijbregts JE; De Vet HCW; Zijlstra JM;
    J Nucl Med; 2018 Dec; 59(12):1831-1836. PubMed ID: 29728515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real world experience of R-CHOP with or without consolidative radiotherapy vs DA-EPOCH-R in the first-line treatment of primary mediastinal B-cell lymphoma.
    Chan EHL; Koh LP; Lee J; De Mel S; Jeyasekharan A; Liu X; Tang T; Lim ST; Tao M; Quek R; Farid Bin Harunal Ras M; Lee YS; Diong C; Tan D; Kim SJ; Chee YL; Poon LMM
    Cancer Med; 2019 Aug; 8(10):4626-4632. PubMed ID: 31264808
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001.
    Persky DO; Li H; Stephens DM; Park SI; Bartlett NL; Swinnen LJ; Barr PM; Winegarden JD; Constine LS; Fitzgerald TJ; Leonard JP; Kahl BS; LeBlanc ML; Song JY; Fisher RI; Rimsza LM; Smith SM; Miller TP; Friedberg JW
    J Clin Oncol; 2020 Sep; 38(26):3003-3011. PubMed ID: 32658627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. R-CHOP therapy alone in limited stage diffuse large B-cell lymphoma.
    Tomita N; Takasaki H; Miyashita K; Fujisawa S; Ogusa E; Matsuura S; Kishimoto K; Numata A; Fujita A; Ohshima R; Kuwabara H; Hagihara M; Hashimoto C; Takemura S; Koharazawa H; Yamazaki E; Fujimaki K; Taguchi J; Sakai R; Ishigatsubo Y
    Br J Haematol; 2013 May; 161(3):383-8. PubMed ID: 23432318
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma.
    Dunleavy K; Little RF; Pittaluga S; Grant N; Wayne AS; Carrasquillo JA; Steinberg SM; Yarchoan R; Jaffe ES; Wilson WH
    Blood; 2010 Apr; 115(15):3017-24. PubMed ID: 20130244
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404).
    Swinnen LJ; Li H; Quon A; Gascoyne R; Hong F; Ranheim EA; Habermann TM; Kahl BS; Horning SJ; Advani RH
    Br J Haematol; 2015 Jul; 170(1):56-65. PubMed ID: 25823885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial.
    Jin J; Ji D; Xia Z; Xue K; Zhang Q; Liu Y; Cao J; Hong X; Gu JJ; Guo Y; Lv F
    BMC Cancer; 2022 Apr; 22(1):403. PubMed ID: 35418080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R.
    Giulino-Roth L; O'Donohue T; Chen Z; Bartlett NL; LaCasce A; Martin-Doyle W; Barth MJ; Davies K; Blum KA; Christian B; Casulo C; Smith SM; Godfrey J; Termuhlen A; Oberley MJ; Alexander S; Weitzman S; Appel B; Mizukawa B; Svoboda J; Afify Z; Pauly M; Dave H; Gardner R; Stephens DM; Zeitler WA; Forlenza C; Levine J; Williams ME; Sima JL; Bollard CM; Leonard JP
    Br J Haematol; 2017 Dec; 179(5):739-747. PubMed ID: 29082519
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial.
    Schöder H; Polley MC; Knopp MV; Hall N; Kostakoglu L; Zhang J; Higley HR; Kelloff G; Liu H; Zelenetz AD; Cheson BD; Wagner-Johnston N; Kahl BS; Friedberg JW; Hsi ED; Leonard JP; Schwartz LH; Wilson WH; Bartlett NL
    Blood; 2020 Jun; 135(25):2224-2234. PubMed ID: 32232481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase 2 Study of Dose-Reduced Consolidation Radiation Therapy in Diffuse Large B-Cell Lymphoma.
    Kelsey CR; Broadwater G; James O; Chino J; Diehl L; Beaven AW; Chang C; Koontz BF; Prosnitz LR
    Int J Radiat Oncol Biol Phys; 2019 Sep; 105(1):96-101. PubMed ID: 30858144
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma.
    Yang DH; Min JJ; Song HC; Jeong YY; Chung WK; Bae SY; Ahn JS; Kim YK; Bom HS; Chung IJ; Kim HJ; Lee JJ
    Eur J Cancer; 2011 Jun; 47(9):1312-8. PubMed ID: 21334197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
    Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
    Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Value of surveillance studies for patients with stage I to II diffuse large B-cell lymphoma in the rituximab era.
    Hiniker SM; Pollom EL; Khodadoust MS; Kozak MM; Xu G; Quon A; Advani RH; Hoppe RT
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):99-106. PubMed ID: 25863757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial.
    Hüttmann A; Rekowski J; Müller SP; Hertenstein B; Franzius C; Mesters R; Weckesser M; Kroschinsky F; Kotzerke J; Ganser A; Bengel FM; La Rosée P; Freesmeyer M; Höffkes HG; Hertel A; Behringer D; Prange-Krex G; Griesshammer M; Holzinger J; Wilop S; Krohn T; Raghavachar A; Maschmeyer G; Brink I; Schroers R; Gaska T; Bernhard H; Giagounidis A; Schütte J; Dienst A; Hautzel H; Naumann R; Klein A; Hahn D; Pöpperl G; Grube M; Marienhagen J; Schwarzer A; Kurch L; Höhler T; Steiniger H; Nückel H; Südhoff T; Römer W; Brinkmann M; Ose C; Alashkar F; Schmitz C; Dürig J; Hoelzer D; Jöckel KH; Klapper W; Dührsen U
    Ann Hematol; 2019 Apr; 98(4):897-907. PubMed ID: 30610279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
    Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E;
    Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
    Poeschel V; Held G; Ziepert M; Witzens-Harig M; Holte H; Thurner L; Borchmann P; Viardot A; Soekler M; Keller U; Schmidt C; Truemper L; Mahlberg R; Marks R; Hoeffkes HG; Metzner B; Dierlamm J; Frickhofen N; Haenel M; Neubauer A; Kneba M; Merli F; Tucci A; de Nully Brown P; Federico M; Lengfelder E; di Rocco A; Trappe R; Rosenwald A; Berdel C; Maisenhoelder M; Shpilberg O; Amam J; Christofyllakis K; Hartmann F; Murawski N; Stilgenbauer S; Nickelsen M; Wulf G; Glass B; Schmitz N; Altmann B; Loeffler M; Pfreundschuh M; ;
    Lancet; 2019 Dec; 394(10216):2271-2281. PubMed ID: 31868632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.